The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing (20 - 21) Manufacture of chemicals and pharmaceuticals 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
250 jobs Number of planned job losses
Announcement Date
28 October 2011
Employment effect (start)
1 December 2011
Foreseen end date
Description
Multinational pharmaceutical company Novo Nordisk, based in Bagsværd outside Copenhagen in Denmark, plans to cut 250 jobs in the European sales division.
Reasons for the restructuring are said to be the pressure on prices of insulin products. It is reported that health reforms and pressures from competitors have decreased growth in the insulin business in Europe to fewer than 3%, Novo informed on 28. October 2011.
Novo has 32000 employees in Europe of which ca. 43% work in Denmark.
Sources
28 October 2011: Borsen.dk
Citation
Eurofound (2011), Novo Nordisk, Internal restructuring in European Union, factsheet number 72794, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/72794.